These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 21747412)

  • 1. Methotrexate consolidation treatment according to pharmacogenetics of MTHFR ameliorates event-free survival in childhood acute lymphoblastic leukaemia.
    Salazar J; Altés A; del Río E; Estella J; Rives S; Tasso M; Navajas A; Molina J; Villa M; Vivanco JL; Torrent M; Baiget M; Badell I
    Pharmacogenomics J; 2012 Oct; 12(5):379-85. PubMed ID: 21747412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Methotrexate toxicity and efficacy during the consolidation phase in paediatric acute lymphoblastic leukaemia and MTHFR polymorphisms as pharmacogenetic determinants.
    D'Angelo V; Ramaglia M; Iannotta A; Crisci S; Indolfi P; Francese M; Affinita MC; Pecoraro G; Napolitano A; Fusco C; Oreste M; Indolfi C; Casale F
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1339-46. PubMed ID: 21590445
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MTHFR 677 (C-->T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95.
    Seidemann K; Book M; Zimmermann M; Meyer U; Welte K; Stanulla M; Reiter A
    Ann Hematol; 2006 May; 85(5):291-300. PubMed ID: 16463153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High dose methotrexate treatment in childhood ALL: pilot study on the impact of the MTHFR 677C>T and 1298A>C polymorphisms on MTX-related toxicity.
    Haase R; Elsner K; Merkel N; Stiefel M; Mauz-Körholz C; Kramm CM; Körholz D
    Klin Padiatr; 2012 Apr; 224(3):156-9. PubMed ID: 22513795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations of novel genetic variations in the folate-related and ARID5B genes with the pharmacokinetics and toxicity of high-dose methotrexate in paediatric acute lymphoblastic leukaemia.
    Csordas K; Lautner-Csorba O; Semsei AF; Harnos A; Hegyi M; Erdelyi DJ; Eipel OT; Szalai C; Kovacs GT
    Br J Haematol; 2014 Aug; 166(3):410-20. PubMed ID: 24712521
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of plasma methotrexate level and MTHFR genotype in Korean paediatric patients with acute lymphoblastic leukaemia.
    Chae H; Kim M; Choi SH; Kim SK; Lee JW; Chung NG; Cho B; Kim Y
    J Chemother; 2020 Sep; 32(5):251-259. PubMed ID: 32431230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
    Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
    Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
    [TBL] [Abstract][Full Text] [Related]  

  • 8. C677T and A1298C polymorphisms of the methylenetetrahydrofolate reductase gene: effect on methotrexate-related toxicity in adult acute lymphoblastic leukaemia.
    Eissa DS; Ahmed TM
    Blood Coagul Fibrinolysis; 2013 Mar; 24(2):181-8. PubMed ID: 23183238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Methotrexate-induced mucositis in acute leukemia patients is not associated with the MTHFR 677T allele in Mexico.
    Ruiz-Argüelles GJ; Coconi-Linares LN; Garcés-Eisele J; Reyes-Núñez V
    Hematology; 2007 Oct; 12(5):387-91. PubMed ID: 17891601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Relationship between the methylenetetrahydrofolate reductase gene polymorphism and adverse reactions of high-dose methotrexate in children with acute lymphocytic leukemia].
    Zheng MM; Yue LJ; Chen XW; Wen FQ; Li CG; Yang CL; Xie C; Ding H
    Zhongguo Dang Dai Er Ke Za Zhi; 2013 Mar; 15(3):201-6. PubMed ID: 23498762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose methotrexate therapy of childhood acute lymphoblastic leukemia: lack of relation between serum methotrexate concentration and creatinine clearance.
    Joannon P; Oviedo I; Campbell M; Tordecilla J
    Pediatr Blood Cancer; 2004 Jul; 43(1):17-22. PubMed ID: 15170885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of pre-hydration and pharmacogenetics on plasma methotrexate concentration and renal dysfunction following high-dose methotrexate therapy.
    Yanagimachi M; Goto H; Kaneko T; Naruto T; Sasaki K; Takeuchi M; Tanoshima R; Kato H; Yokosuka T; Kajiwara R; Fujii H; Tanaka F; Goto S; Takahashi H; Mori M; Kai S; Yokota S
    Int J Hematol; 2013 Dec; 98(6):702-7. PubMed ID: 24241962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of folate pathway polymorphisms on high-dose methotrexate-related toxicity and survival in childhood acute lymphoblastic leukemia.
    Erčulj N; Kotnik BF; Debeljak M; Jazbec J; Dolžan V
    Leuk Lymphoma; 2012 Jun; 53(6):1096-104. PubMed ID: 22074251
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MTHFR polymorphisms' influence on outcome and toxicity in acute lymphoblastic leukemia patients.
    Chiusolo P; Reddiconto G; Farina G; Mannocci A; Fiorini A; Palladino M; La Torre G; Fianchi L; Sorà F; Laurenti L; Leone G; Sica S
    Leuk Res; 2007 Dec; 31(12):1669-74. PubMed ID: 17512587
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Functional variants of gene encoding folate metabolizing enzyme and methotrexate-related toxicity in children with acute lymphoblastic leukemia.
    Kałużna E; Strauss E; Zając-Spychała O; Gowin E; Świątek-Kościelna B; Nowak J; Fichna M; Mańkowski P; Januszkiewicz-Lewandowska D
    Eur J Pharmacol; 2015 Dec; 769():93-9. PubMed ID: 26528799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of methylene tetrahydrofolate reductase polymorphisms and coadministration of antimetabolites on toxicity after high dose methotrexate.
    van Kooten Niekerk PB; Schmiegelow K; Schroeder H
    Eur J Haematol; 2008 Nov; 81(5):391-8. PubMed ID: 18691257
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue.
    Chiusolo P; Giammarco S; Bellesi S; Metafuni E; Piccirillo N; De Ritis D; Marietti S; Federica S; Laurenti L; Fianchi L; Hohaus S; Giuseppe L; Sica S
    Cancer Chemother Pharmacol; 2012 Mar; 69(3):691-6. PubMed ID: 21984221
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study of the pharmacokinetic and pharmacogenetic contribution to the toxicity of high-dose methotrexate in children with acute lymphoblastic leukemia.
    El-Khodary NM; El-Haggar SM; Eid MA; Ebeid EN
    Med Oncol; 2012 Sep; 29(3):2053-62. PubMed ID: 21644011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prevention of CNS recurrence in childhood ALL: results with reduced radiotherapy combined with CNS-directed chemotherapy in four consecutive ALL-BFM trials.
    Schrappe M; Reiter A; Henze G; Niemeyer C; Bode U; Kühl J; Gadner H; Havers W; Plüss H; Kornhuber B; Zintl F; Ritter J; Urban C; Niethammer D; Riehm H
    Klin Padiatr; 1998; 210(4):192-9. PubMed ID: 9743952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of genetic polymorphism in the folate metabolic pathway with methotrexate pharmacokinetics and toxicity in childhood acute lymphoblastic leukaemia and malignant lymphoma.
    Faganel Kotnik B; Grabnar I; Bohanec Grabar P; Dolžan V; Jazbec J
    Eur J Clin Pharmacol; 2011 Oct; 67(10):993-1006. PubMed ID: 21509569
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.